Opiant Pharmaceuticals Inc (NASDAQ:OPNT) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus target price of $47.00 for the company and are predicting that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Opiant Pharmaceuticals an industry rank of 90 out of 255 based on the ratings given to its competitors.
Several research analysts recently commented on OPNT shares. Cantor Fitzgerald set a $32.00 price objective on shares of Opiant Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 28th. ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 4th.
An institutional investor recently bought a new position in Opiant Pharmaceuticals stock. Northern Trust Corp bought a new position in Opiant Pharmaceuticals Inc (NASDAQ:OPNT) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 24,372 shares of the technology company’s stock, valued at approximately $350,000. Northern Trust Corp owned approximately 0.86% of Opiant Pharmaceuticals at the end of the most recent reporting period. 4.51% of the stock is owned by institutional investors.
OPNT opened at $18.58 on Friday. The company has a market capitalization of $55.42 million, a P/E ratio of 6.32 and a beta of 0.14. Opiant Pharmaceuticals has a 12 month low of $12.75 and a 12 month high of $42.00.
Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings data on Thursday, August 9th. The technology company reported ($0.52) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.07) by $0.55. The company had revenue of $3.15 million during the quarter, compared to the consensus estimate of $2.10 million. Opiant Pharmaceuticals had a negative net margin of 449.52% and a negative return on equity of 471.43%. On average, analysts predict that Opiant Pharmaceuticals will post -4.7 earnings per share for the current year.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Read More: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.